Biotech innovator Liquidia, specializing in pulmonary therapies, reported a notable insider sale amid continued growth in its ...

SAN FRANCISCO, April 17, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) and an executive, seeking to represent investors who purchased ...

Approval was supported by the phase 3 LANDI-PED study, which demonstrated significant heart rate reduction and conversion to normal sinus rhythm in pediatric patients.

Allrock Bio has dosed the first participants in a small clinical trial testing ROC-101 as an add-on treatment for pulmonary ...

Positive airway pressure therapy is linked with reduced pulmonary arterial pressures in patients with severe obstructive sleep apnea or obesity hypoventilation syndrome.

The first participant has been enrolled in a two-part Phase 3 clinical trial testing IKT-001, an experimental treatment for ...

AllRock Bio has dosed the first patients in the Phase IIa ROCSTAR clinical trial investigating ROC-101, an oral ...

In a phase 2 trial, treatment with sotatercept shows reduced pulmonary vascular resistance and heart outcomes in patients ...

Scientists have created a new "molecular map" uncovering how an important human receptor involved in blood clotting and ...

A diagnosis of Leigh syndrome is often devastating for families. The rare genetic disorder steadily robs the brain and ...

A University of Alberta research team has found a genetic variant that can be used to identify which patients with pulmonary arterial hypertension need the most urgent care. "This could potentially ...

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension (“PAH”), announced today that ...